Literature DB >> 21900400

Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer.

Chunpeng Zhang1, Liguo Wang2, Dayong Wu1, Hongyan Chen1, Zhong Chen1, Jennifer M Thomas-Ahner3, Debra L Zynger4, Jérôme Eeckhoute5, Jindan Yu6, Jun Luo7, Myles Brown8, Steven K Clinton3, Kenneth P Nephew9, Tim H-M Huang10, Wei Li2, Qianben Wang1.   

Abstract

The enhancer pioneer transcription factor FoxA1 is a global mediator of steroid receptor (SR) action in hormone-dependent cancers. In castration-resistant prostate cancer (CRPC), FoxA1 acts as an androgen receptor cofactor to drive G₂ to M-phase cell-cycle transit. Here, we describe a mechanistically distinct SR-independent role for FoxA1 in driving G₁ to S-phase cell-cycle transit in CRPC. By comparing FoxA1 binding sites in prostate cancer cell genomes, we defined a codependent set of FoxA1-MYBL2 and FoxA1-CREB1 binding sites within the regulatory regions of the Cyclin E2 and E2F1 genes that are critical for CRPC growth. Binding at these sites upregulate the Cyclin E2 and Cyclin A2 genes in CRPC but not in earlier stage androgen-dependent prostate cancer, establishing a stage-specific role for this pathway in CRPC growth. Mechanistic investigations indicated that FoxA1, MYBL2, or CREB1 induction of histone H3 acetylation facilitated nucleosome disruption as the basis for codependent transcriptional activation and G₁ to S-phase cell-cycle transit. Our findings establish FoxA1 as a pivotal driver of the cell-cycle in CRPC which promotes G₁ to S-phase transit as well as G₂ to M-phase transit through two distinct mechanisms. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900400      PMCID: PMC4081454          DOI: 10.1158/0008-5472.CAN-11-1882

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  E2Fs link the control of G1/S and G2/M transcription.

Authors:  Wencheng Zhu; Paloma H Giangrande; Joseph R Nevins
Journal:  EMBO J       Date:  2004-10-28       Impact factor: 11.598

Review 2.  B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer.

Authors:  Arturo Sala
Journal:  Eur J Cancer       Date:  2005-09-29       Impact factor: 9.162

3.  Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome.

Authors:  L A Cirillo; C E McPherson; P Bossard; K Stevens; S Cherian; E Y Shim; K L Clark; S K Burley; K S Zaret
Journal:  EMBO J       Date:  1998-01-02       Impact factor: 11.598

4.  Expression and role of Foxa proteins in prostate cancer.

Authors:  Janni Mirosevich; Nan Gao; Aparna Gupta; Scott B Shappell; Richard Jove; Robert J Matusik
Journal:  Prostate       Date:  2006-07-01       Impact factor: 4.104

5.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

Authors:  Sooryanarayana Varambally; Jianjun Yu; Bharathi Laxman; Daniel R Rhodes; Rohit Mehra; Scott A Tomlins; Rajal B Shah; Uma Chandran; Federico A Monzon; Michael J Becich; John T Wei; Kenneth J Pienta; Debashis Ghosh; Mark A Rubin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

6.  A new human prostate carcinoma cell line, 22Rv1.

Authors:  R M Sramkoski; T G Pretlow; J M Giaconia; T P Pretlow; S Schwartz; M S Sy; S R Marengo; J S Rhim; D Zhang; J W Jacobberger
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Jul-Aug       Impact factor: 2.416

Review 7.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 1.

Authors:  R E Sobel; M D Sadar
Journal:  J Urol       Date:  2005-02       Impact factor: 7.450

8.  Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells.

Authors:  K E Knudsen; K C Arden; W K Cavenee
Journal:  J Biol Chem       Date:  1998-08-07       Impact factor: 5.157

9.  Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers.

Authors:  J M Gudas; M Payton; S Thukral; E Chen; M Bass; M O Robinson; S Coats
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

10.  Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.

Authors:  Z Culig; J Hoffmann; M Erdel; I E Eder; A Hobisch; A Hittmair; G Bartsch; G Utermann; M R Schneider; K Parczyk; H Klocker
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more
  51 in total

Review 1.  The mutational landscape of prostate cancer.

Authors:  Christopher E Barbieri; Chris H Bangma; Anders Bjartell; James W F Catto; Zoran Culig; Henrik Grönberg; Jun Luo; Tapio Visakorpi; Mark A Rubin
Journal:  Eur Urol       Date:  2013-05-18       Impact factor: 20.096

2.  Mapping mutations in prostate cancer exomes.

Authors:  Benjamin Sunkel; Qianben Wang
Journal:  Asian J Androl       Date:  2012-07-30       Impact factor: 3.285

Review 3.  Interrogating genomic and epigenomic data to understand prostate cancer.

Authors:  Jung Kim; Jindan Yu
Journal:  Biochim Biophys Acta       Date:  2012-01-03

4.  FOXA1 transcriptionally up-regulates cyclin B1 expression to enhance chondrosarcoma progression.

Authors:  Zong-Shin Lin; Chiao-Chen Chung; Yu-Chia Liu; Tsung-Ming Chen; Yung-Luen Yu; Shao-Chun Wang; Ya-Huey Chen
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

5.  FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.

Authors:  Xiaoyong Fu; Rinath Jeselsohn; Resel Pereira; Emporia F Hollingsworth; Chad J Creighton; Fugen Li; Martin Shea; Agostina Nardone; Carmine De Angelis; Laura M Heiser; Pavana Anur; Nicholas Wang; Catherine S Grasso; Paul T Spellman; Obi L Griffith; Anna Tsimelzon; Carolina Gutierrez; Shixia Huang; Dean P Edwards; Meghana V Trivedi; Mothaffar F Rimawi; Dolores Lopez-Terrada; Susan G Hilsenbeck; Joe W Gray; Myles Brown; C Kent Osborne; Rachel Schiff
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-06       Impact factor: 11.205

Review 6.  Role of steroid receptor and coregulator mutations in hormone-dependent cancers.

Authors:  Anna C Groner; Myles Brown
Journal:  J Clin Invest       Date:  2017-04-03       Impact factor: 14.808

7.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Authors:  Christopher E Barbieri; Sylvan C Baca; Michael S Lawrence; Francesca Demichelis; Mirjam Blattner; Jean-Philippe Theurillat; Thomas A White; Petar Stojanov; Eliezer Van Allen; Nicolas Stransky; Elizabeth Nickerson; Sung-Suk Chae; Gunther Boysen; Daniel Auclair; Robert C Onofrio; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Karen Sheikh; Terry Vuong; Candace Guiducci; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Wasay M Hussain; Alex H Ramos; Wendy Winckler; Michelle C Redman; Kristin Ardlie; Ashutosh K Tewari; Juan Miguel Mosquera; Niels Rupp; Peter J Wild; Holger Moch; Colm Morrissey; Peter S Nelson; Philip W Kantoff; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nat Genet       Date:  2012-05-20       Impact factor: 38.330

8.  Epidaurus: aggregation and integration analysis of prostate cancer epigenome.

Authors:  Liguo Wang; Haojie Huang; Gregory Dougherty; Yu Zhao; Asif Hossain; Jean-Pierre A Kocher
Journal:  Nucleic Acids Res       Date:  2014-11-05       Impact factor: 16.971

Review 9.  Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.

Authors:  William Hankey; Zhong Chen; Qianben Wang
Journal:  Cancer Res       Date:  2020-02-24       Impact factor: 12.701

Review 10.  AR function in promoting metastatic prostate cancer.

Authors:  Michael A Augello; Robert B Den; Karen E Knudsen
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.